Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4025-4032

  Hsieh, Tze Chen ^a   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

EGCG; Genistein; Phytochemical synergy; Prostate cancer cells; Quercetin

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; EPIGALLOCATECHIN GALLATE; GENISTEIN; PROTEIN P53; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASIAN; BIOAVAILABILITY; CANCER CELL CULTURE; CAUCASIAN; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITOMETRY; DIETARY INTAKE; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATECHIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CULTURE MEDIA, SERUM-FREE; DRUG SYNERGISM; GENE EXPRESSION; GENISTEIN; HUMANS; MALE; NEOPLASTIC STEM CELLS; PHYTOTHERAPY; PROSTATIC NEOPLASMS; QUERCETIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 71949123654     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Hsing AW and Devesa SS: Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23: 3-13, 2001.
2. Hsing AW, Tsao L and Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85: 60-67, 2000.
3. Coldman AJ, Phillips N and Pickles TA: Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. Canadian Medical Association J 168: 31-35, 2003. (Pubitemid 36241178)
4. Krongrad A, Lai S and Vidal EM: The significance of changing trends in prostate cancer incidence and mortality. Semin Urol Oncol 16: 30-34, 1998. (Pubitemid 28108427)
5. Quinn M and Babb P: Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90: 162-173, 2002.
6. Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH and Chen J: Changing trends of prostate cancer in Asia. Aging Male 7: 120-132, 2004.
7. Baade PD, Coory MD and Aitken JF: International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control 15: 237-241, 2004.
8. Hsing AW, Devesa SS, Jin F and Gao YT: Rising incidence of prostate cancer in Shanghai, China. Cancer Epidemiol Biomarkers Prev 7: 83-84, 1998. (Pubitemid 28087146)
9. Marks LS, Kojima M, Demarzo A, Heber D, Bostwick DG, Qian J, Dorey FJ, Veltri RW, Mohler JL and Partin AW: Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. Urology 64: 765-771, 2004. (Pubitemid 39446059)
10. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE and Mack TM: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63: 963-966, 1991.
11. Cook LS, Goldoft M, Schwartz SM and Weiss NS: Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 161: 152-155, 1999. (Pubitemid 29422310)
12. Watanabe M, Nakayama T, Shiraishi T, Stemmermann GN and Yatani R: Comparative studies of prostate cancer in Japan versus the United States. A review. Urol Oncol J: 274-283, 2000.
13. Holzbeierlein JM, Mcintosh J and Thrasher JB: The role of soy phytoestrogens in prostate cancer. Curr Opin Urol 15: 17-22, 2005. (Pubitemid 40105520)
14. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT and Hsing AW: Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 72: 665-668, 2003. (Pubitemid 36899850)
15. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R and Elgavish A: Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 132: 552S-558S, 2002. (Pubitemid 34208769)
16. Morton MS, Arisaka O, Miyake N, Morgan LD and Evans BA: Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 132: 3168-3171, 2002.
17. Magee PJ and Rowland IR: Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91: 513-531, 2004.
18. Fischer L, Mahoney C, Jeffcoat AR, Koch MA, Thomas BE, Valentine JL, Stinchcombe T, Boan J, Crowell JA and Zeisel SH: Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 48: 160-170, 2004. (Pubitemid 39045777)
19. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W and Peto R: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334: 1145-1149, 1996. (Pubitemid 26137972)
20. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S and Hammar S: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150-1155, 1996. (Pubitemid 26137973)
21. Taylor PR and Greenwald P: Nutritional interventions in cancer prevention. J Clin Oncol 23: 333-345, 2005.
22. Greenwald P: Clinical trials in cancer prevention: current results and perspectives for the future. J Nutr 134: 3507S-3512S, 2004.
23. Liu RH: Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr 78: 517S-520S, 2003.
24. Manson MM, Farmer PB, Gescher A and Steward WP: Innovative agents in cancer prevention. Recent Results Cancer Res 166: 257-275, 2005.
25. Paolini M, Abdel-Rahman SZ, Sapone A, Pedulli GF, Perocco P. Cantelli-Forti G and Ugator MS: Beta-carotene: a cancer chemopreventive agent or a co-carcinogen? Mutat Res 543: 195-200, 2003.
26. Gescher AJ, Sharma RA and Steward WP: Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol 2: 371-379, 2001.
27. Kline K, Yu W and Sanders BG: Vitamin E and breast cancer. J Nutr 134: 3458S-3462S, 2004.
28. Liu RH: Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 134: 3479S-3485S, 2004.
29. Pappa G, Strathmann J, Lowinger M, Bartsch H and Gerhauser C: Quantitative combination effects between sulforaphane and 3,3′- diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis 28: 1471-1477, 2007. (Pubitemid 47241796)
30. Elson CE: Tropical oils: nutritional and scientific issues. Crit Rev Food Sci Nutr 31: 79-102, 1992.
31. Sugano M, Koba K and Tsuji E: Health benefits of rice bran oil. Anticancer Res 19: 3651-3657, 1999.
32. Conte C, Floridi A, Aisa C, Piroddi M and Galli F: Gamma-tocotrienol metabolism and antiproliferative effect in prostate cancer cells. Ann N Y Acad Sci 1031: 391-394, 2004. (Pubitemid 40361787)
33. Agarwal R: Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60: 1051-1059, 2000.
34. Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, Lubahn DB and Macdonald RS: Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer 49: 200-208, 2004. (Pubitemid 39487880)
35. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W and Yang CS: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63: 7563-7570, 2003. (Pubitemid 37466673)
36. Hsieh TC, Burfeind P, Laud K, Backer JM, Traganos F, Darzynkiewicz Z and Wu JM: Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int J Oncol 15: 245-252, 1999.
37. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the Chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337: 224-231, 2005.
38. Hsieh TC and Wu JM: Differential control of growth, cell cycle progression, and gene expression in human estrogen receptor positive MCF-7 breast cancer cells by extracts derived from polysaccharopeptide I'm-Yunity and Danshen and their combination. Int J Oncol 29: 1215-1222, 2006.
39. Hsieh TC, Wu P, Park S and Wu JM: Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP). BMC Complement Altern Med 6: 30-44, 2006.
40. Chaudhary A and Willett KL: Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort. Toxicology 217: 194-205, 2006. (Pubitemid 41773835)
41. Kyle E, Neckers L, Takimoto C, Curt G and Bergan R: Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 51: 193-200, 1997. (Pubitemid 27074139)
42. Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC and Schantz SP: Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 7: 351-354, 1998. (Pubitemid 28354149)
43. Kim S, Lee MJ, Hong J, Li C, Smith TJ, Yang GY, Seril DN and Yang CS: Plasma and tissue levels of tea catechins in rats and mice during chronic consumption of green tea polyphenols. Nutr Cancer 37: 41-48, 2000. (Pubitemid 30650665)
44. Hong J, Lu H, Meng X, Ryu JH, Hara Y and Yang CS: Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3- gallate in HT-29 human colon adenocarcinoma cells. Cancer Res 62: 7241-7246, 2002. (Pubitemid 36025245)
45. Cronauer MV, Schulz WA, Burchardt T, Ackermann R and Burchardt M: Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23: 3541-3549, 2004. (Pubitemid 38658420)
46. Asher G, Lotem J, Cohen B, Sachs L and Shaul Y: Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA 98: 1188-1193, 2001. (Pubitemid 32121208)
47. Gong X, Kole L, Iskander K and Jaiswal AK: NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res 67: 5380-5388, 2007. (Pubitemid 46997278)